What is CMO?

PharmaTek's directory lets sourcing teams shortlist manufacturing partners and screen them against FDA compliance signals before engaging.

A CMO takes a sponsor's existing, validated manufacturing process and runs it to produce drug product at clinical or commercial scale. The defining feature is that the process, formulation, and analytical methods already exist — the CMO supplies the capacity, equipment, and GMP-compliant facility to execute them, rather than developing the process itself.

CMOs operate across the same dosage forms as in-house plants — oral solids, sterile injectables, semi-solids, and packaging — and are often engaged for a single step (for example, sterile fill-finish) rather than the whole chain. Because the process is transferred in, a successful CMO engagement depends heavily on a clean technology transfer.

The difference is scope. A CMO provides manufacturing capacity against a process that is already developed and validated. A CDMO adds development — it can build or optimize the process, methods, and formulation before manufacturing. If you arrive with a finished, validated process and need someone to make it, that is a CMO engagement; if you need the process developed too, that is a CDMO.

The market has blurred this line: many traditional CMOs have added development services and now brand themselves as CDMOs. As with any sourcing label, the capability and regulatory record matter more than the acronym on the website.

A CMO fits when the process is already locked down and the need is capacity: launching a product without building a plant, adding a second source to reduce concentration risk, expanding into a new geography, or freeing internal lines for higher-value work. Because no development is involved, engagements can move faster and cost less than a full CDMO program.

The principal risk is the technology transfer itself and ongoing supply dependency, which is why many teams qualify more than one manufacturer for a critical product.

Qualifying a CMO means confirming capability and dosage-form fit, available capacity and lead time, robust quality systems and GMP status, and a clean regulatory record. An open FDA Warning Letter, recurring Form 483 observations, or a recall history at a candidate site are concrete sourcing risks that capacity figures alone will not reveal.

Sourcing teams typically issue a structured RFI to a shortlist, compare quality and capacity responses side by side, and screen each site against live compliance signals before a quality audit. PharmaTek's directory screens manufacturing partners against FDA recalls, Warning Letters, and Form 483 observations so those flags surface before you engage.